Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 14Recruiting 12Not yet recruiting 3Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27venetoclax 25Specimen Handling 25Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Docetaxel 22Biopsy 22Radiotherapy 21Ipilimumab 21Bevacizumab 21Azacitidine 21Radiosurgery 18Dexamethasone 18durvalumab 17Fluorouracil 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14tislelizumab 13Leucovorin 13Cytarabine 13olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × capivasertib × 1 year × Clear all
NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡